What is HC Wainwright's Forecast for AUPH Q2 Earnings?

Key Points

• HC Wainwright forecasts Aurinia Pharmaceuticals (NASDAQ:AUPH) will achieve earnings per share of $0.16 in Q2 2025, with a "Buy" rating and a target price of $17.00.
• Aurinia Pharmaceuticals reported earnings of $0.16 per share in its latest quarter, exceeding expectations, with a revenue of $62.47 million.
• Institutional investors recently increased their positions in Aurinia, with 36.83% of the stock now held by institutional shareholders.

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Free Report) TSE: AUP - Stock analysts at HC Wainwright issued their Q2 2025 EPS estimates for shares of Aurinia Pharmaceuticals in a report issued on Wednesday, July 30th. HC Wainwright analyst A. He expects that the biotechnology company will post earnings of $0.16 per share for the quarter. HC Wainwright currently has a "Buy" rating and a $17.00 target price on the stock. The consensus estimate for Aurinia Pharmaceuticals' current full-year earnings is $0.11 per share. HC Wainwright also issued estimates for Aurinia Pharmaceuticals' Q3 2025 earnings at $0.18 EPS, Q4 2025 earnings at $0.19 EPS, FY2025 earnings at $0.69 EPS, FY2026 earnings at $0.68 EPS, FY2027 earnings at $0.59 EPS, FY2028 earnings at $0.57 EPS and FY2029 earnings at $0.81 EPS.

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last released its earnings results on Thursday, July 31st. The biotechnology company reported $0.16 earnings per share for the quarter, missing analysts' consensus estimates of $0.17 by ($0.01). The business had revenue of $70.01 million during the quarter, compared to analysts' expectations of $64.27 million. Aurinia Pharmaceuticals had a return on equity of 20.06% and a net margin of 23.31%.

Separately, Royal Bank Of Canada raised their target price on shares of Aurinia Pharmaceuticals from $8.00 to $9.00 and gave the stock an "outperform" rating in a research note on Friday.

Aurinia Pharmaceuticals Stock Up 2.0%

Shares of NASDAQ:AUPH traded up $0.23 during midday trading on Friday, reaching $11.68. The company's stock had a trading volume of 1,764,505 shares, compared to its average volume of 1,564,093. The firm has a market capitalization of $1.54 billion, a P/E ratio of 27.13 and a beta of 1.23. The firm has a 50 day moving average of $8.35 and a 200-day moving average of $8.14. Aurinia Pharmaceuticals has a 12-month low of $5.20 and a 12-month high of $11.76. The company has a quick ratio of 4.63, a current ratio of 5.23 and a debt-to-equity ratio of 0.18.

Hedge Funds Weigh In On Aurinia Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in the company. GF Fund Management CO. LTD. purchased a new stake in Aurinia Pharmaceuticals in the fourth quarter valued at approximately $27,000. Tower Research Capital LLC TRC boosted its position in Aurinia Pharmaceuticals by 368.5% in the 4th quarter. Tower Research Capital LLC TRC now owns 3,350 shares of the biotechnology company's stock worth $30,000 after purchasing an additional 2,635 shares in the last quarter. Vermillion & White Wealth Management Group LLC purchased a new stake in Aurinia Pharmaceuticals in the 4th quarter worth approximately $31,000. GAMMA Investing LLC boosted its position in Aurinia Pharmaceuticals by 56.1% in the 1st quarter. GAMMA Investing LLC now owns 4,852 shares of the biotechnology company's stock worth $39,000 after purchasing an additional 1,744 shares in the last quarter. Finally, MAI Capital Management purchased a new stake in Aurinia Pharmaceuticals in the 1st quarter worth approximately $39,000. 36.83% of the stock is currently owned by institutional investors.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.